Reports

Drug name	NICE TAs	Comments
Betamethasone valerate 0.1% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Bevacizumab (Avastin®) injection	TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Bevacizumab infusion (Avastin®)	TA178 - Bevacizumab (first-line), sorafenib (first and second line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA285 - Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	Negative NICE TA & hospital use only.
Bimekizumab	TA723 - Bimekizumab for treating moderate to severe plaque psoriasis TA916 - Bimekizumab for treating active psoriatic arthritis
Blinatumomab	TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	Hospital use only
Bortezomib injection	TA228 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA129 - Bortezomib monotherapy for relapsed multiple myeloma TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	National CDF list. Hospital use only.
Bosutinib	TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Botox A	TA260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab injection	TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	National CDF list. For hospital use only.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports